xylyx

News

XYLYX BIO releases highly physiologic 2D substrates for improved antifibrotic drug discovery

Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH.

Webinar: Transforming lung fibrosis drug discovery with the IN MATRICO® Human Lung Fibrosis platform

Lung extracellular matrix (ECM) is implicated in the pathogenesis and progression of lung fibrosis. Current preclinical lung fibrosis models do not incorporate lung ECM, and therefore lack the defining part of the fibrotic lung disease environment.

In this webinar, we describe the paradigm shift in drug discovery from ‘in vitro’ to ‘in matrico’, and present our Human Lung Fibrosis platform for disease modeling and compound testing. Leveraging human fibrotic lung ECM and corresponding clinical data, the platform increases the relevance of cell-based assays and enables lung fibrosis modeling with clinical context to accelerate drug development.

  • Please fill out the form below to gain access to the video.
  • This field is for validation purposes and should be left unchanged.

Allevi Partners with Xylyx Bio to Create Liver Specific Bioinks

Only a handful of researchers and companies around the world are tackling liver-specific bioinks, and one of them is now Allevi. The Philadelphia-based biotech company has now partnered with Xylyx Bio, a pioneer in physiomimetic biomaterials, to introduce new tissue-specific bioinks with Decellularized Extracellular Matrix (dECM). Starting with the liver, they will seek to recapitulate the native tissue microenvironment in 3D bioprinting.